Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).

Details

Language :

English

ISSN :

14215721

Volume :

53

Database :

Complementary Index

Journal :

Current Problems in Dermatology

Publication Type :

Academic Journal

Accession number :

126175875

Full Text :

https://doi.org/10.1159/000478081